128 related articles for article (PubMed ID: 7273015)
21. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
[TBL] [Abstract][Full Text] [Related]
22. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
Von Hoff DD; Pollard E; Kuhn J; Murray E; Coltman CA
Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of ICRF-187 using a daily for 3 days schedule.
Von Hoff DD; Howser D; Lewis BJ; Holcenberg J; Weiss RB; Young RC
Cancer Treat Rep; 1981; 65(3-4):249-52. PubMed ID: 6786738
[TBL] [Abstract][Full Text] [Related]
24. [Phase I study of 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea (TA-077). Phase I Study Group].
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2425-33. PubMed ID: 3729497
[TBL] [Abstract][Full Text] [Related]
25. Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.
Spiegel RJ; Blum RH; Levin M; Pinto CA; Wernz JC; Speyer JL; Hoffman KS; Muggia FM
Cancer Res; 1982 Jan; 42(1):354-8. PubMed ID: 7053862
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
27. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
Vokes EE; Goh BC; Bertucci D; Vogelzang NJ; Mani S; Ratain MJ
Cancer; 1999 Aug; 86(3):528-32. PubMed ID: 10430263
[TBL] [Abstract][Full Text] [Related]
28. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of mitoxantrone by 24-hour continuous infusion.
Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
31. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
Supko JG; Balcerzak SP; Kraut EH
Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of 6-diazo-5-oxo-L-norleucine (DON) administered by 5-day courses.
Earhart RH; Koeller JM; Davis HL
Cancer Treat Rep; 1982 May; 66(5):1215-7. PubMed ID: 7083223
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of two schedules of teroxirone.
Rubin J; Kovach JS; Ames MM; Moertel CG; Creagan ET; O'Connell MJ
Cancer Treat Rep; 1987 May; 71(5):489-92. PubMed ID: 3567975
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.
Roberts JD; Stewart JA; McCormack JJ; Krakoff IR; Culham CA; Hartshorn JN; Newman RA; Haugh LD; Young JA
Cancer Treat Rep; 1987 Feb; 71(2):141-9. PubMed ID: 3802111
[TBL] [Abstract][Full Text] [Related]
35. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
Cowens JW; Creaven PJ; Greco WR; Brenner DE; Tung Y; Ostro M; Pilkiewicz F; Ginsberg R; Petrelli N
Cancer Res; 1993 Jun; 53(12):2796-802. PubMed ID: 8504422
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of N-methylformamide.
McVie JG; ten Bokkel Huinink WW; Simonetti G; Dubbelman R
Cancer Treat Rep; 1984 Apr; 68(4):607-10. PubMed ID: 6325001
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial and pharmacokinetics of a daily x 5 schedule of 3-deazauridine.
Creaven PJ; Priore RL; Mittelman A; Bruno S; Henderson ES; Rustum YM; Solomon JK
Cancer Treat Rep; 1982 Jan; 66(1):81-4. PubMed ID: 7053271
[TBL] [Abstract][Full Text] [Related]
38. Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug.
Alberts DS; Griffith KS; Goodman GE; Herman TS; Murray E
Cancer Chemother Pharmacol; 1980; 5(1):11-5. PubMed ID: 7460190
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC
Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
[TBL] [Abstract][Full Text] [Related]
40. [Phase II study of mitoxantrone].
Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]